This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FYB201

Santo Holding GMBH

Drug Names(s): FYB-201, FYB 201, Biosimilar Lucentis , Biosimilar Lucentis (Formycon), Biosimilar ranibizumab

Description: FYB201 is a biosimilar of Roche's approved drug, Lucentis.

Lucentis is the antigen-binding fragment of a humanized anti-VEGF antibody. VEGF activity is critical to the growth of blood vessels that occurs in age-related macular degeneration (AMD).

Deal Structure: Formycon and Santo Holding
In December 2013, Formycon announced the signing of an exclusive, worldwide licensing agreement with Santo Holding, granting rights to the first biosimilar drug of Formycons development pipeline.

Under the terms of the agreement, Santo Holding will assume responsibility and bear the costs for the development and commercialization of the Formycon biosimilar drug. Formycon will perform the entire further development of the product for Santo Holding.

Formycon will receive an immediate, single-digit million euro up-front payment and will be entitled to additional payments in the three-digit million euro range based upon the attainment of specific regulatory and sales results.

Partners: Formycon AG


FYB201 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug